Jenna Kahn, MD
Radiation Oncology · Portland, ORNPI 1366855793
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by GT Medical Technologies, Inc at 31.0% of the total. Reporting peaked in 2021 at $1,140 and has fallen 93.8% since, to $71 in 2025.
Across 11 payments — averaging $146.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GT Medical Technologies, Inc$500
- E.r. Squibb & Sons, L.L.C.$500
- Elekta, Inc.$244
- Novocure Inc.$163
- Boston Scientific$91
- Merck$71
- plus $41 from 2 others
What the payments were for
- Consulting fees$50031%
- Speaking & faculty fees$50031%
- Food & beverage$58236%
- Entertainment$282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GT Medical Technologies, Inc | 1 | $500 |
| E.r. Squibb & Sons, L.L.C. | 1 | $500 |
| Elekta, Inc. | 3 | $244 |
| Novocure Inc. | 1 | $163 |
| Boston Scientific | 2 | $91 |
| Merck | 1 | $71 |
| Civatech Oncology, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,610 in reported general payments places this provider in the 80th percentile of 93 radiation oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 39 | $594 |
| Ondansetron OdtOndansetron | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Portland
- Marka CrittendenPortland$20K
- Steven SeungPortland$11K
- Joshua WalkerPortland$9K
- Andrew KeePortland$7K
- Brandon DyerPortland$4K
- Nima NabavizadehPortland$4K
- Amar SrivastavaPortland$4K
- Re-I ChinPortland$3K
- Akanksha RajeursPortland$2K
- Matthew SolhjemPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.